A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
NCT07180771 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2026-01-28
Summary
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
Conditions
- Peripheral T Cell Lymphoma
Interventions
- DRUG
-
BR101801
Patients will receive 200mg capsules (100mg+100mg)
Sponsors & Collaborators
-
Boryung Pharmaceutical Co., Ltd
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-28
- Primary Completion
- 2027-09-30
- Completion
- 2027-09-30
More Related Trials
-
Bortezomib in Treating Patients With Mantle Cell Lymphoma
NCT00030875 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
NCT01504776 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
NCT00958256 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
NCT03487133 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
NCT01470131 ·Status: TERMINATED ·Phase: PHASE3
-
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
NCT07018050 ·Status: RECRUITING ·Phase: PHASE2
-
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
NCT01078142 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
NCT00103272 ·Status: TERMINATED ·Phase: PHASE1
-
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
NCT00088855 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
NCT00216697 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
NCT01381692 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
NCT04061772 ·Status: UNKNOWN ·Phase: PHASE2
-
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
NCT07257510 ·Status: RECRUITING ·Phase: NA
-
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
NCT02474563 ·Status: COMPLETED
-
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00963274 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
NCT02902965 ·Status: COMPLETED ·Phase: PHASE2
-
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
NCT00752518 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
NCT00723359 ·Status: COMPLETED ·Phase: PHASE1
-
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
NCT00310037 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
NCT05920876 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
NCT00813150 ·Status: COMPLETED ·Phase: PHASE3
-
Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.
NCT02797041 ·Status: UNKNOWN
-
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
NCT00334932 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2